Abstract: An in vivo assay to measure anchorage-independent growth and phenotypic stability of a certain cell population comprising subcutaneous or intramuscular injection in a mammal of a cell suspension of articular chondrocytes in an iso-osmotic liquid, the same suspension comprising articular chondrocytes in an amount equivalent to at least 1×106 chondrocytes as applied to immune-deficient mice. The outcome is linked to molecular markers. The present invention further relates to DNA chips and diagnostic tools comprising the latter to predict the outcome of ACT. Antibodies raised against positive and negative markers of chondrocyte stability can also be used for quality control on the chondrocytes. Therapeutical composition comprising stable chondrocytes are very useful for tissue repair.
Type:
Grant
Filed:
November 25, 2008
Date of Patent:
July 28, 2015
Assignee:
TIGENIX N.V.
Inventors:
Frank Luyten, Cosimo De Bari, Francesco Dell'Accio
Abstract: Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor ? having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body.
Type:
Application
Filed:
January 3, 2011
Publication date:
June 30, 2011
Applicant:
Tigenix n.v.
Inventors:
Frank LUYTEN, Cosimo DE BARI, Francesco DELL'ACCIO
Abstract: Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor ? having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body.
Type:
Grant
Filed:
July 18, 2008
Date of Patent:
January 4, 2011
Assignee:
Tigenix N.V.
Inventors:
Frank Luyten, Cosimo De Bari, Francesco Dell'Accio
Abstract: The present invention disclosed the expression of CXCL6 by cells which are able to form stable cartilage. The invention describes the use of these cells and of CXCL6 to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects. The invention further describes the use of chemokines in the modulation of progenitor cell differentiation.
Type:
Grant
Filed:
December 29, 2008
Date of Patent:
November 30, 2010
Assignee:
Tigenix N.V.
Inventors:
Frank Luyten, Cosimo De Bari, Francesco Dell'Accio
Abstract: The present invention relates to a set of genes which can be used to predict the potential of a cell population to form cartilage when implanted in vivo. The set of markers is used inter alia as a quality control of cells and in screening assays to evaluate the impact of compounds and conditions on the cartilage forming ability of cells.
Type:
Application
Filed:
November 23, 2007
Publication date:
March 18, 2010
Applicant:
TIGENIX N.V.
Inventors:
Frank Luyten, Cosimo De Bari, Francesco Dell'Accio
Abstract: The present invention relates to regulatory cells, which are capable of restoring, maintaining or improving the stable cartilage phenotype of expanded and passaged chondrocytes. These regulatory cells are also capable of directing precursor and stem cells into the chondrogenic lineage. An enriched population of regulatory cells can be obtained by harvesting the non-adherent cells in the culture medium of a monolayer culture of PO chondrocytes.
Abstract: An in vivo assay to measure anchorage-independent growth and phenotypic stability of a certain cell population comprising subcutaneous or intramuscular injection in a mammal of a cell suspension of articular chondrocytes in an iso-osmotic liquid, the same suspension comprising articular chondrocytes in an amount equivalent to at least 1×106 chondrocytes as applied to immune-deficient mice. The outcome is linked to molecular markers. The present invention further relates to DNA chips and diagnostic tools comprising the latter to predict the outcome of ACT. Antibodies raised against positive and negative markers of chondrocyte stability can also be used for quality control on the chondrocytes. Therapeutical composition comprising stable chondrocytes are very useful for tissue repair.
Type:
Application
Filed:
November 25, 2008
Publication date:
June 25, 2009
Applicant:
Tigenix N.V.
Inventors:
Frank LUYTEN, Cosimo De Bari, Francesco Dell'Accio
Abstract: Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor ? having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body.
Type:
Application
Filed:
July 18, 2008
Publication date:
May 14, 2009
Applicant:
Tigenix n.v.
Inventors:
Frank LUYTEN, Cosimo DE BARI, Francesco DELL'ACCIO
Abstract: The present invention disclosed the expression of CXCL6 by cells which are able to form stable cartilage. The invention describes the use of these cells and of CXCL6 to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects. The invention further describes the use of chemokines in the modulation of progenitor cell differentiation.
Type:
Application
Filed:
December 29, 2008
Publication date:
May 7, 2009
Applicant:
Tigenix N.V.
Inventors:
Frank LUYTEN, Cosimo DE BARI, Francesco DELL'ACCIO
Abstract: The present invention disclosed the expression of CXCL6 by cells which are able to form stable cartilage. The invention describes the use of these cells and of CXCL6 to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects. The invention further describes the use of chemokines in the modulation of progenitor cell differentiation.
Type:
Grant
Filed:
August 12, 2004
Date of Patent:
February 3, 2009
Assignee:
Tigenix N.V.
Inventors:
Frank Luyten, Cosimo De Bari, Francesco Dell'Accio
Abstract: An in vivo assay to measure anchorage-independent growth and phenotypic stability of a certain cell population comprising subcutaneous or intramuscular injection in a mammal of a cell suspension of articular chondrocytes in an iso-osmotic liquid, the same suspension comprising articular chondrocytes in an amount equivalent to at least 1×106 chondrocytes as applied to immune-deficient mice. The outcome is linked to molecular markers. The present invention further relates to DNA chips and diagnostic tools comprising the latter to predict the outcome of ACT. Antibodies raised against positive and negative markers of chondrocyte stability can also be used for quality control on the chondrocytes. Therapeutical compositions comprising stable chondrocytes are very useful for tissue repair.
Type:
Grant
Filed:
April 24, 2003
Date of Patent:
January 27, 2009
Assignee:
Tigenix N.V.
Inventors:
Frank Luyten, Cosimo De Bari, Francesco Dell'Accio